The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

A Clinical Guide to Supportive and Palliative Care for HIV/AIDS • Topic IndexCTfindings in HAD, 217cultural carecommunication concerns, 435grieving, 332history taking, 53of immigrants, 320–321information resources, 530–531overview, 301–302palliative care discussions, 440–441, 441rural poor, 473–474symptom assessment difficulties, 57custody, of children, 384–385. see also guardianscytochrome P450 enzyme systemCYP3A4, 555inducers, 241, 557, 565inhibitors, 241, 557, 565overview, 555psychotropics interactions, 556–559ritonavir interactions, 560substrates, 241, 558, 559cytokinespruritis, 180Ddeathapproaching signs, 469–471discomfort with, 442imminence, 498–499planning for, 464–465preparing for, 496, 496–498, 497prognostication, 493–495, 494provider perspective, 27–28signs of, 499death rattle, 143–145debts, 382decisionmakingfor children, 280–283, 282legal options, 374–378shared process, 352–353dehydrationdiarrhea patients, 159expectoration, 143in terminal patients, 137–138deliberation principlecase study, 358–359discussion, 352–353limitations, 353–354deliriumcauses, 222vs. depression, 226at end of life, 499, 500misperceptions, 224opioids, 109symptom assessment difficulties, 56dementiacauses, 213–214clinical findings, 216–217CNS manifestations, 217criteria, 214vs. depression, 226differential diagnosis, 213late stage treatment, 222presentation, 211–213, 212vs. progressive multifocal leukoencephalopathy(PML), 219risk factor, 214demodex infestation, 186–188dependence, drug, 259, 261depressionin children, 278common medications, 228manifestation, 225misperceptions, 224dermatophytosesdiagnosis, 194presentation, 193treatment, 194developing countriesbarriers to care, 390–391care models, 401–403drug availability, 398–401education efforts, 395–398policy, 392–394recommendations for, 403–404diagnosisdisclosure to children, 283–284vs. symptoms, 39–41diarrheain children, 277drug causes, 563medication absorption, 551treatment options, 157–159, 159dieticians, 450dignity, 349–350, 469disability insurance, 366–367, 369–370discharge planning, 457–458disenfranchisement, 331, 339disseminated mycobacterium avium complex(MAC), 129distraction, 116distress, 45, 56diversion, 261domestic violence, 224double effect rulecase study, 359–362, 361discussion, 353–355explained, 139drug eruptions, 197–198drug resistance, 480–482, 481drug toxicity, 16dry mouthcaries, 169at end of life, 500in terminal patients, 137durable power of attorney, 377dying. see deathdysphagia, 162dyspneacauses, 146–147in children, 278treatment options, 145–150Eecthyma, 188eczema craquele, 183, 203eczemas, 183–185Edmonton Symptom Assessment Scale (ESAS),64–65, 77–79education, of caregivers, 422elderly, special concerns, 316–317emotional expression, 336emotional health, 412, 487. see also specificemotionsemotional skills, 270employment, 369–370, 373–374U.S. Department of Health and Human Services • Health Resources and Services Administration • HIV/AIDS Bureau 589INDEX